News
-
Almirall has announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the company’s aclidinium bromide/formoterol fumarate DPI for the treatment of COPD. Almirall will market the product as… Read more . . .
-
Monash University will license technology related to inhaled oxytocin for the treatment of postpartum hemorrhage to to GSK, the university and GSK have announced. Monash and GSK will collaborate on development through early clinical trials,… Read more . . .
-
According to Boehringer Ingelheim, the FDA has approved the company’s Spiriva Respimat tiotropium bromide inhalation soft mist inhaler for the treatment of COPD. In August 2014, the FDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted in… Read more . . .
-
According to Invion, the company has successfully completed the first stage of feasibility studies for its INV102 inhaled nadolol, which it intends to develop for the treatment of asthma, COPD, and cystic fibrosis. Invion is… Read more . . .
-
Acorda Therapeutics has announced that it will acquire inhaled drug developer Civitas Therapeutics, including rights to the ARCUS inhalation platform, for $525 million in cash. The deal includes worldwide rights to Civitas’s lead candidate, CVT-301… Read more . . .
-
Dr. Reddy’s Laboratories have announced that the company has launched generic levalbuterol inhalation solution in the US as of September 23, 2014. The generic version of Sunovion’s Xopenex is available in 0.31 mg /3 mL,… Read more . . .
-
NovaBiotics has announced that its Lynovex (NM001) cysteamine for the treatment of cystic fibrosis has been granted orphan drug designation by the FDA. NovaBiotics is developing both oral and dry powder inhalation formulations of the… Read more . . .
-
According to Mylan, the company will initiate a Phase 3 clinical trial of its generic version of Advair/Seretide Diskus for the treatment of asthma in October 2014, with an expected completion in April 2015. Mylan… Read more . . .
-
Almac subsidiary Galen Ltd will pay Medical Developments International (MVP) approximately A$650,000 (~US$587,000) up front for a license to market and distribute MVP’s Penthrox inhaled methoxyflurane in the UK and Ireland. The deal also includes… Read more . . .
-
According to Kind Consumer, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the company’s Voke nicotine inhaler for general sale. The company said that the license is “for use to relieve and/or… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.